PROTAGONIST THERAPEUTICS

Serial Number 87814966
602

Registration Progress

Application Filed
Feb 28, 2018
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

PROTAGONIST THERAPEUTICS

Basic Information

Serial Number
87814966
Filing Date
February 28, 2018
Abandonment Date
July 10, 2019
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Aug 7, 2019
Classes
042

Rights Holder

Protagonist, Inc.

03
Address
Suite 140
7707 Gateway Blvd.
Newark, CA 94560

Ownership History

Protagonist, Inc.

Original Applicant
03
Newark, CA

Legal Representation

Attorney
DAVID A. JACKSON

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

14 events
Date Code Type Description Documents
Aug 7, 2019 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Aug 7, 2019 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Jan 9, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 9, 2019 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 9, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 15, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 14, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 14, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 15, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 15, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 15, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 12, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 7, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 3, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific research, pharmaceutical research, medical research; technical and scientific consultation and product development services, including for others, in the fields of immune mediated diseases, inflammatory diseases, and rare diseases; research and development of new products pertaining to the treatment of immune mediated diseases, inflammatory diseases, and rare diseases, and to pharmaceuticals; providing on line information for medical research purposes, in the fields of immune mediated diseases, inflammatory diseases, and rare diseases, treatments for immune mediated diseases, inflammatory diseases, and rare diseases, and pharmaceuticals

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"